These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
131 related articles for article (PubMed ID: 27760202)
21. Neoadjuvant chemotherapy followed by concurrent chemoradiotherapy versus concurrent chemoradiotherapy alone in locoregionally advanced nasopharyngeal carcinoma: A phase III multicentre randomised controlled trial. Cao SM; Yang Q; Guo L; Mai HQ; Mo HY; Cao KJ; Qian CN; Zhao C; Xiang YQ; Zhang XP; Lin ZX; Li WX; Liu Q; Qiu F; Sun R; Chen QY; Huang PY; Luo DH; Hua YJ; Wu YS; Lv X; Wang L; Xia WX; Tang LQ; Ye YF; Chen MY; Guo X; Hong MH Eur J Cancer; 2017 Apr; 75():14-23. PubMed ID: 28214653 [TBL] [Abstract][Full Text] [Related]
22. Concurrent chemoradiotherapy with or without cetuximab for stage II to IVb nasopharyngeal carcinoma: a case-control study. Li Y; Chen QY; Tang LQ; Liu LT; Guo SS; Guo L; Mo HY; Chen MY; Guo X; Cao KJ; Qian CN; Zeng MS; Bei JX; Shao JY; Sun Y; Tan J; Chen S; Ma J; Zhao C; Mai HQ BMC Cancer; 2017 Aug; 17(1):567. PubMed ID: 28836950 [TBL] [Abstract][Full Text] [Related]
23. Diabetes, prediabetes and the survival of nasopharyngeal carcinoma: a study of 5,860 patients. OuYang PY; Su Z; Tang J; Lan XW; Mao YP; Deng W; Xie FY PLoS One; 2014; 9(10):e111073. PubMed ID: 25350747 [TBL] [Abstract][Full Text] [Related]
24. Risk subset of the survival for nasopharyngeal carcinoma patients with bone metastases: who will benefit from combined treatment? Cao X; Han Y; He L; Xiang J; Wen Z Oral Oncol; 2011 Aug; 47(8):747-52. PubMed ID: 21665523 [TBL] [Abstract][Full Text] [Related]
25. Treatment outcomes and late toxicities of 869 patients with nasopharyngeal carcinoma treated with definitive intensity modulated radiation therapy: new insight into the value of total dose of cisplatin and radiation boost. Ou X; Zhou X; Shi Q; Xing X; Yang Y; Xu T; Shen C; Wang X; He X; Kong L; Ying H; Hu C Oncotarget; 2015 Nov; 6(35):38381-97. PubMed ID: 26485757 [TBL] [Abstract][Full Text] [Related]
26. Prognostic Value of Circulating Lipoprotein in Patients with Locoregionally Advanced Nasopharyngeal Carcinoma. Yao JJ; He XJ; Lawrence WR; Zhang WJ; Kou J; Zhang F; Zhou GQ; Wang SY; Sun Y Cell Physiol Biochem; 2018; 48(1):285-292. PubMed ID: 30011397 [TBL] [Abstract][Full Text] [Related]
27. IMRT combined with concurrent chemotherapy plus adjuvant chemotherapy versus IMRT combined with concurrent chemotherapy alone in patients with nasopharyngeal carcinoma. Zhong Q; Zhu X; Li L; Qu S; Liang Z; Zeng F; Pan X Oncotarget; 2017 Jun; 8(24):39683-39694. PubMed ID: 28147309 [TBL] [Abstract][Full Text] [Related]
28. Implication of comorbidity on the initiation of chemotherapy and survival outcomes in patients with locoregionally advanced nasopharyngeal carcinoma. Guo R; Mao YP; Chen L; Tang LL; Zhou GQ; Liu LZ; Tian L; Zeng MS; Jia WH; Shao JY; Lin AH; Ma J Oncotarget; 2017 Feb; 8(6):10594-10601. PubMed ID: 27070084 [TBL] [Abstract][Full Text] [Related]
29. Effects of hepatitis B virus infection and antiviral therapy on the clinical prognosis of nasopharyngeal carcinoma. Weng JJ; Wei JZ; Li M; Lu JL; Qin YD; Jiang H; Qu SH Cancer Med; 2020 Jan; 9(2):541-551. PubMed ID: 31774249 [TBL] [Abstract][Full Text] [Related]
30. Prognostic Value of Cervical Nodal Necrosis in Nasopharyngeal Carcinoma: Analysis of 1800 Patients with Positive Cervical Nodal Metastasis at MR Imaging. Lan M; Huang Y; Chen CY; Han F; Wu SX; Tian L; Zheng L; Lu TX Radiology; 2015 Aug; 276(2):536-44. PubMed ID: 25759968 [TBL] [Abstract][Full Text] [Related]
31. Elevated plasma fibrinogen level shows superior prognostic value than Epstein-Barr virus DNA load for stage IVA/B nasopharyngeal carcinoma patients in the intensity-modulated radiotherapy era. Lan M; Chen C; Huang Y; Mao M; Han F; Liao J; Deng M; Duan Z; Zheng L; Wu S; Lu T; Jian Y Oncotarget; 2016 Jul; 7(29):46242-46252. PubMed ID: 27323828 [TBL] [Abstract][Full Text] [Related]
32. Advanced-Stage Nasopharyngeal Carcinoma: Restaging System after Neoadjuvant Chemotherapy on the Basis of MR Imaging Determines Survival. Liu LT; Chen QY; Tang LQ; Zhang L; Guo SS; Xie CM; Liu XW; Guo L; Mo HY; Chen MY; Zhao C; Guo X; Cao KJ; Qian CN; Zeng MS; Bei JX; Hong MH; Shao JY; Sun Y; Ma J; Mai HQ Radiology; 2017 Jan; 282(1):171-181. PubMed ID: 27479804 [TBL] [Abstract][Full Text] [Related]
33. A retrospective study comparing the outcomes and toxicities of intensity-modulated radiotherapy versus two-dimensional conventional radiotherapy for the treatment of children and adolescent nasopharyngeal carcinoma. Qiu WZ; Peng XS; Xia HQ; Huang PY; Guo X; Cao KJ J Cancer Res Clin Oncol; 2017 Aug; 143(8):1563-1572. PubMed ID: 28342002 [TBL] [Abstract][Full Text] [Related]
34. Effect of adaptive replanning in patients with locally advanced nasopharyngeal carcinoma treated by intensity-modulated radiotherapy: a propensity score matched analysis. Luo Y; Qin Y; Lang J Clin Transl Oncol; 2017 Apr; 19(4):470-476. PubMed ID: 27718153 [TBL] [Abstract][Full Text] [Related]
35. The Prognostic Value of Treatment-Related Lymphopenia in Nasopharyngeal Carcinoma Patients. Liu LT; Chen QY; Tang LQ; Guo SS; Guo L; Mo HY; Chen MY; Zhao C; Guo X; Qian CN; Zeng MS; Bei JX; Tan J; Chen S; Hong MH; Shao JY; Sun Y; Ma J; Mai HQ Cancer Res Treat; 2018 Jan; 50(1):19-29. PubMed ID: 28392551 [TBL] [Abstract][Full Text] [Related]
36. Prognostic Correlations between ABO Blood Group and Pre-Treatment Plasma Epstein-Barr Virus DNA in Patients with Nasopharyngeal Carcinoma Receiving Intensity-Modulated Radiotherapy. Peng H; Chen L; Li WF; Zhang Y; Liu LZ; Tian L; Lin AH; Sun Y; Ma J PLoS One; 2016; 11(11):e0166194. PubMed ID: 27835689 [TBL] [Abstract][Full Text] [Related]
37. High expression of IMPDH2 is associated with aggressive features and poor prognosis of primary nasopharyngeal carcinoma. Xu Y; Zheng Z; Gao Y; Duan S; Chen C; Rong J; Wang K; Yun M; Weng H; Ye S; Zhang J Sci Rep; 2017 Apr; 7(1):745. PubMed ID: 28389646 [TBL] [Abstract][Full Text] [Related]
38. Induction chemotherapy followed by concurrent chemoradiotherapy versus concurrent chemoradiotherapy alone in stage III-IVb nasopharyngeal carcinoma patients with Epstein-Barr virus DNA ≥4000 copies/ml: a matched study. Guo SS; Tang LQ; Chen QY; Zhang L; Liu LT; Guo L; Mo HY; Luo DH; Huang PY; Xiang YQ; Sun R; Chen MY; Wang L; Lv X; Zhao C; Guo X; Cao KJ; Qian CN; Zeng MS; Bei JX; Hong MH; Shao JY; Sun Y; Ma J; Mai HQ Oncotarget; 2016 May; 7(20):29739-48. PubMed ID: 27105538 [TBL] [Abstract][Full Text] [Related]
39. Prognostic value of chronic hepatitis B virus infection in patients with nasopharyngeal carcinoma: analysis of 1301 patients from an endemic area in China. Liu X; Li X; Jiang N; Lei Y; Tang LL; Chen L; Zhou GQ; Sun Y; Yue D; Guo R; Mao YP; Li WF; Liu LZ; Tian L; Lin AH; Ma J Cancer; 2014 Jan; 120(1):68-76. PubMed ID: 24114075 [TBL] [Abstract][Full Text] [Related]
40. Correlation of PD-L1 Expression of Tumor Cells with Survival Outcomes after Radical Intensity-Modulated Radiation Therapy for Non-Metastatic Nasopharyngeal Carcinoma. Lee VH; Lo AW; Leung CY; Shek WH; Kwong DL; Lam KO; Tong CC; Sze CK; Leung TW PLoS One; 2016; 11(6):e0157969. PubMed ID: 27341634 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]